APP and Alzheimer disease: The reason for this is that the treatment was implemented at different conditions (i.e., AACD versus AD), indistinguishable to us due to the current inability to detect the T1 crossing in human patients (practically, the T1 crossing can be ascertained only via the detection of the operation of the AβPP-independent iAβ production pathway, not feasible currently in human subjects).